TFXTeleflex Incorporated

$138.75

The financials

Teleflex Incorporated by the numbers

Teleflex Incorporated (TFX) reported revenue of $570M in Q2 2026 (quarter ended June 30, 2026), up 29% from the same quarter a year earlier. That came with a gross margin of 58% and net income of $100M (17% of revenue). For the full year FY2025, revenue was $1.99B (+17% year on year) and net income −$906M. Its largest product in 2026-Q1 was Vascular Access at $237M, 43% of the disclosed total, just ahead of Interventional at 37%.

Teleflex Incorporated income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$570M$443M+29%
Gross profit$332M$266M+25%
Operating income$73M$91M−20%
Net income$100M$123M−19%
Diluted EPS$2.28$2.77−18%
Revenue by product, 2026-Q1, as reported to the SEC
ProductRevenueShare
Vascular Access$237M43%
Interventional$205M37%
Surgical$107M19%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q1 2026Total $548.3M (-40%)
Interventional grew +104% year on yearVascular Access +8.1% year on year
  • Vascular Access$236.8MQoQ +24%year on year +8.1%
  • Interventional$204.7MQoQ -23%year on year +104%
  • Surgical$106.8MQoQ -13%year on year +12%
  • Anesthesia-QoQ -year on year -
  • Interventional Urology-QoQ -year on year -
  • Oem-QoQ -year on year -
  • Other-QoQ -year on year -
Segment sum = 100% of reported consolidated revenue · Latest source: 10-Q filed 2026-05-07, SEC EDGAR